Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients

Abstract

Criteria of response to IFN-beta therapy in RRMS using disability progression are more clinically relevant than those based only in relapse rate. This finding may be important for the counseling and care of RRMS patients treated with IFN-beta.